Search

Displaying results 5261 - 5270 of 7018 in total
  1. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  2. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. … It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

  3. Drug

    α-Methylfentanyl

    go.drugbank.com/drugs/DB01557
    ExperimentalIllicit

    α-Methylfentanyl is an analog of fentanyl with opioid analgesic properties.

  4. Drug

    D-Leucine

    go.drugbank.com/drugs/DB01746
    Experimental

    An essential branched-chain amino acid important for hemoglobin formation. [PubChem]

  5. Drug

    Aniracetam

    go.drugbank.com/drugs/DB04599
    Investigational

    Compound with anti-depressive properties used as a mental performance enhancer.

  6. Drug

    Famzeretcel

    go.drugbank.com/drugs/DB17906
    Investigational

    jCell is an human retinal progenitor cell therapy for retinitis pigmentosa.

  7. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  8. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.

  9. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856].

  10. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.